{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:34:21Z","timestamp":1791221661194,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1053\/j.jvca.2013.01.008","type":"journal-article","created":{"date-parts":[[2013,5,11]],"date-time":"2013-05-11T07:15:28Z","timestamp":1368256528000},"page":"620-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Progress in Platelet Blockers: The Target is the P2Y12 Receptor"],"prefix":"10.1053","volume":"27","author":[{"given":"Prakash A.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.T.","family":"Augoustides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2013.01.008_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.109.853069","article-title":"New P2Y12 inhibitors","volume":"121","author":"Cattaneo","year":"2010","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2013.01.008_bib2","article-title":"P2Y(12) receptor: Platelet thrombus formation and medical interventions","author":"Mohelmani","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1053\/j.jvca.2013.01.008_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1756-8722-4-44","article-title":"Novel agents for antiplatelet therapy","volume":"4","author":"Ji","year":"2011","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.jvca.2013.01.008_bib4","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1586\/erc.12.127","article-title":"Modern antiplatelet agents in coronary artery disease","volume":"10","author":"Power","year":"2012","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1053\/j.jvca.2013.01.008_bib5","first-page":"167","article-title":"Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome","volume":"30","author":"Tam","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"10.1053\/j.jvca.2013.01.008_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1160\/TH10-07-0482","article-title":"Mode of action of P2Y12 antagonists as inhibitors of platelet function","volume":"105","author":"Iyu","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.jvca.2013.01.008_bib7","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.jvca.2007.03.011","article-title":"Pro: Continuation of aspirin\/clopidogrel for cardiac surgery","volume":"21","author":"van der Linden","year":"2007","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2013.01.008_bib8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1053\/j.jvca.2010.04.017","article-title":"Progress in platelet medicine: Focus on stent thrombosis and drug resistance","volume":"24","author":"Patel","year":"2010","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2013.01.008_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ahj.2007.04.014","article-title":"Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis","volume":"154","author":"Snoep","year":"2007","journal-title":"Am Heart J"},{"issue":"suppl 1","key":"10.1053\/j.jvca.2013.01.008_bib10","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.thromres.2012.08.275","article-title":"New antiplatelet agents: The end of resistance?","volume":"130","author":"Kastrati","year":"2012","journal-title":"Thromb Res"},{"key":"10.1053\/j.jvca.2013.01.008_bib11","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.athoracsur.2012.07.086","article-title":"2012 Update to the Society of Thoracic Surgeons guideline on the use of antiplatelet drugs in patients having cardiac and noncardiac operations","volume":"94","author":"Ferraris","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.jvca.2013.01.008_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/imi.0b013e3182747699","article-title":"Drugs, devices, technologies and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: A consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011","volume":"7","author":"Menkis","year":"2012","journal-title":"Innovations (Philadelphia)"},{"key":"10.1053\/j.jvca.2013.01.008_bib13","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/j.jvca.2012.02.015","article-title":"Perioperative management of antiplatelet agents in patients undergoing cardiac surgery","volume":"26","author":"Lavi","year":"2012","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2013.01.008_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.jvca.2011.07.024","article-title":"Update on blood conservation for cardiac surgery","volume":"26","author":"Nalla","year":"2012","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2013.01.008_bib15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1053\/j.jvca.2012.06.015","article-title":"Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma","volume":"26","author":"Tanaka","year":"2012","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2013.01.008_bib16","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2013.01.008_bib17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.clpt.6100139","article-title":"Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently","volume":"81","author":"Farid","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.jvca.2013.01.008_bib18","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCINTERVENTIONS.112.972463","article-title":"Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high dose clopidogrel versus prasugrel: The RESET GENE trial","volume":"5","author":"Sardella","year":"2012","journal-title":"Circ Cardiovasc Intervent"},{"key":"10.1053\/j.jvca.2013.01.008_bib19","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2013.01.008_bib20","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2013.01.008_bib21","article-title":"Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: Weighing the benefits and risks of prasugrel versus clopidogrel","author":"Salisbury","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1053\/j.jvca.2013.01.008_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","article-title":"Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease","volume":"29","author":"Wallentin","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2013.01.008_bib23","article-title":"Ticagrelor: The first novel reversible P2Y12 inhibitor","author":"Htun","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1053\/j.jvca.2013.01.008_bib24","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2013.01.008_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-2005-869525","article-title":"Preclinical and clinical studies with selective reversible direct P2Y12 inhibitors","volume":"31","author":"van Giezen","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.jvca.2013.01.008_bib26","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1345\/aph.1M548","article-title":"Efficacy and safety of ticagrelor: A reversible P2Y12 receptor antagonist","volume":"44","author":"Anderson","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.jvca.2013.01.008_bib27","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","article-title":"Ticagrelor binds to the human P2Y receptor independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation","volume":"7","author":"van Giezen","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.jvca.2013.01.008_bib28","article-title":"Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor with aspirin in healthy volunteers","author":"Teng","year":"2012","journal-title":"Platelets"},{"key":"10.1053\/j.jvca.2013.01.008_bib29","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2013.01.008_bib30","article-title":"Impact of clopidogrel and potent P2Y12 inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention\u2014Systematic review and meta-analysis","author":"Aradi","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.jvca.2013.01.008_bib31","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1161\/STROKEAHA.112.668988","article-title":"Comparing ticagrelor versus clopidogrel in patients with a history of cerebrovascular disease: A net clinical harm","volume":"43","author":"Dinicotantonio","year":"2012","journal-title":"Stroke"},{"key":"10.1053\/j.jvca.2013.01.008_bib32","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1161\/CIRCULATIONAHA.112.111930","article-title":"Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke","volume":"125","author":"Verheugt","year":"2012","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2013.01.008_bib33","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1161\/CIRCULATIONAHA.111.082727","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack","volume":"125","author":"James","year":"2012","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2013.01.008_bib34","article-title":"Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study","author":"Kohli","year":"2012","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2013.01.008_bib35","unstructured":"Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST elevation myocardial infarction. Circ Cardiovasc Intervent [Epub ahead of print]"},{"key":"10.1053\/j.jvca.2013.01.008_bib36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2012.03.050","article-title":"Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention","volume":"60","author":"Alexopoulos","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2013.01.008_bib37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ahj.2012.10.013","article-title":"Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention","volume":"165","author":"Park","year":"2013","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2013.01.008_bib38","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MCA.0b013e3283564930","article-title":"A brief review of the past and future of platelet P2Y12 antagonist","volume":"23","author":"Bam","year":"2012","journal-title":"Coron Artery Dis"},{"issue":"suppl 1","key":"10.1053\/j.jvca.2013.01.008_bib39","first-page":"75","article-title":"Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors","volume":"105","author":"Storey","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.jvca.2013.01.008_bib40","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2013.01.008_bib41","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2013.01.008_bib42","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMe0910677","article-title":"Cangrelor\u2014A champion lost in translation","volume":"361","author":"Kastrati","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2013.01.008_bib43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2013.01.008_bib44","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0022-5223(97)70414-8","article-title":"Tirofiban provides platelet anesthesia during cardiopulmonary bypass in baboons","volume":"113","author":"Hiramatsu","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.jvca.2013.01.008_bib45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.thromres.2008.01.001","article-title":"Platelet anesthesia during extracorporeal circulation: Differential effects of GP IIb\/IIIa blockers on platelet activation marker P-selectin expression at hypothermia","volume":"122","author":"Straub","year":"2008","journal-title":"Thromb Res"},{"key":"10.1053\/j.jvca.2013.01.008_bib46","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/bja\/aer518","article-title":"Short-acting P2Y12 blockade to reduce platelet dysfunction and coagulopathy during experimental extracorporeal circulation and hypothermia","volume":"108","author":"Krajewski","year":"2012","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.jvca.2013.01.008_bib47","first-page":"354","article-title":"Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost","volume":"5","author":"Antoniou","year":"2002","journal-title":"Heart Surg Forum"},{"key":"10.1053\/j.jvca.2013.01.008_bib48","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jtcvs.2003.08.042","article-title":"Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost","volume":"127","author":"Palatianos","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.jvca.2013.01.008_bib49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00000542-200102000-00013","article-title":"Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban","volume":"94","author":"Koster","year":"2001","journal-title":"Anesthesiology"},{"key":"10.1053\/j.jvca.2013.01.008_bib50","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/j.jvca.2010.12.015","article-title":"Update in hematology: Heparin-induced thrombocytopenia and bivalirudin","volume":"25","author":"Augoustides","year":"2011","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2013.01.008_bib51","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ahj.2011.11.001","article-title":"Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction","volume":"163","author":"White","year":"2012","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2013.01.008_bib52","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ahj.2012.02.018","article-title":"Rationale and design of the cangrelor versus standard therapy to achieve optimal management of platelet inhibition PHOENIX trial","volume":"163","author":"Leonardi","year":"2012","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2013.01.008_bib53","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2174\/157016112801784576","article-title":"Novel antiplatelet therapy in acute coronary syndromes: What is new in the pipeline?","volume":"10","author":"Muller","year":"2012","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1053\/j.jvca.2013.01.008_bib54","first-page":"340","article-title":"Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events","volume":"11","author":"Oestrich","year":"2010","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1053\/j.jvca.2013.01.008_bib55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ahj.2010.04.008","volume":"160","author":"Leonardi","year":"2010","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2013.01.008_bib56","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/CIRCINTERVENTIONS.111.964197","volume":"5","author":"Welsh","year":"2012","journal-title":"Circ Cardiovasc Intervent"},{"key":"10.1053\/j.jvca.2013.01.008_bib57","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCINTERVENTIONS.111.965608","volume":"5","author":"Angiolillo","year":"2012","journal-title":"Circ Cardiovasc Intervent"},{"key":"10.1053\/j.jvca.2013.01.008_bib58","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.ahj.2009.10.010","volume":"158","author":"Berger","year":"2009","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2013.01.008_bib59","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCINTERVENTIONS.112.970319","article-title":"Rapid P2Y12 inhibition: Still an unmet medical need","volume":"5","author":"Silvain","year":"2012","journal-title":"Circ Cardiovasc Intervent"},{"key":"10.1053\/j.jvca.2013.01.008_bib60","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1160\/TH12-03-0180","article-title":"Viewpoint: Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel","volume":"108","author":"Serebruany","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.jvca.2013.01.008_bib61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/CRD.0b013e3182099d86","article-title":"Ticagrelor: A novel reversible oral antiplatelet agent","volume":"19","author":"Nawarskas","year":"2011","journal-title":"Cardiol Rev"},{"key":"10.1053\/j.jvca.2013.01.008_bib62","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1160\/TH12-08-0547","article-title":"Why does ticagrelor cause dyspnea?","volume":"108","author":"Cattneo","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.jvca.2013.01.008_bib63","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/01.anes.0000278993.89189.1d","article-title":"Perioperative thrombotic risk of coronary artery stents: Possible role for intravenous platelet blockade","volume":"107","author":"Augoustides","year":"2007","journal-title":"Anesthesiology"},{"key":"10.1053\/j.jvca.2013.01.008_bib64","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/HPC.0b013e31826c53cd","article-title":"Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation","volume":"11","author":"Huang","year":"2012","journal-title":"Crit Pathw Cardiol"},{"key":"10.1053\/j.jvca.2013.01.008_bib65","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/ACO.0b013e3283402aa7","article-title":"Is it time to re-evaluate the routines about stopping\/keeping platelet inhibitors in conjunction to ambulatory surgery?","volume":"23","author":"Serwin","year":"2010","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1053\/j.jvca.2013.01.008_bib66","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1213\/ANE.0b013e318203f38d","article-title":"Antiplatelet drugs: A review of their pharmacology and management in the perioperative period","volume":"112","author":"Hall","year":"2011","journal-title":"Anesth Analg"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077013000165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077013000165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T07:41:58Z","timestamp":1760946118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077013000165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1053077013000165"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2013.01.008","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in Platelet Blockers: The Target is the P2Y12 Receptor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2013.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}